300436.SZ
广生堂
SZSE · Healthcare · C 制造业 · CN
CNY 89.66
−3.72%Sep 4, 2026, 10:27 UTC
GST-Peak-Triple, a triple all-oral regimen for chronic hepatitis B developed by Fujian Gsoon Zhonglin Biotech, a subsidiary of Gsoon Group, completed first patient enrollment and dosing in a Phase II clinical trial.
Source:Sep 1, 2026, 09:36 UTC
Shareholder Zhangzhou Yuanshan Big Health Industry Investment Fund Partnership (Limited Partnership) saw its stake in Ganshantang passively diluted from 5.02% to 4.76% after not participating in the new share issuance, falling below the 5% threshold.
Source:Sep 1, 2026, 09:36 UTC
Ganshantang issued 8.7594 million new A-shares to specific investors, increasing total share capital from 159 million to 168 million shares, with the new shares listing on the Shenzhen Stock Exchange on September 3, 2026.
Aug 28, 2026, 09:13 UTC
Gansheng completed a private placement of A-shares, raising net proceeds of 710 million yuan.
Source:Aug 28, 2026, 09:13 UTC
Gansheng's hepatitis B innovative drug Nairui Kewei GST-HG141 completed enrollment of all 578 subjects in its Phase III clinical trial.
Source:Aug 28, 2026, 09:13 UTC
Gansheng announced its H1 2026 results: revenue of 209 million yuan, net loss of 66.6881 million yuan.
Source: